Influx Healthtech Limited
Influx Healthtech Limited, established in September 2020, specializes in contract manufacturing for B2B clients in nutraceuticals, cosmetics, and more, providing comprehensive services from product formulation to commercialization.
What Influx files
- Others24
- Investor Meet22
- Important10
- Board Meeting6
- Updates5
- PPTs2
Influx Healthtech reported strong Q1 growth, driven by nutraceuticals. It invested ₹10 Cr to expand its nutraceutical facility to 75,000 sq. ft., aiming for a 2.5x capacity increase by August. New lines for beverages and pet nutrition were also added. Management guides FY27 topline growth at 25-30% and EBITDA margins...
Influx Healthtech confirmed it does not qualify as a 'Large Corporate.' The company reports NIL outstanding borrowings, a key factor in this classification. This reflects a debt-free operational status.
Influx Healthtech saw robust Q4FY26 performance, driven by ~₹5 Cr+ capex in new tech like Quick Snap, Liquid Gel Sachet, and a 1,000 kg/hr Pet Food Line. Innovation included Liposomal products. A new B2C subsidiary, OLAHEY WELLNESS, will focus on beverages/snacking. Export readiness improved via Tanzania audit.
Influx Healthtech secured GMP compliance from Tanzania Bureau of Standards for its facility. This greenlights food supplement product registration in Tanzania, boosting international market expansion for 5 years. Big positive for global growth!
Influx Healthtech reports robust operational performance, shifting to value-led innovation. Capacity expansion, new tech like Quick Snap™, and a strengthened order book provide strong revenue visibility. Management expects continued momentum, focusing on clinical nutrition, cosmetic innovation, and complex premium categories.